NEW YORK (GenomeWeb News) - Stratagene yesterday said first-quarter revenues were steady as R&D spending dipped nearly 10 percent and profit increased 25 percent.
 
Total receipts for the three months ended March 31, 2007, rose slightly to $24.4 million from $24.3 million year over year.
 
R&D spending fell slightly to $3.1 million from $3.4 million.
 
The company said net income rose to $1.4 million from $1.1 million in the year-ago period.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.

The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.

Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.

In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.